208191-56-4

Usage

Uses

Used in Pharmaceutical Industry:
(3S,4R)-3-[(1R)-1-(tert-butyldimethylsilyloxy)ethyl]-4-[(6R)-2-(E)-(pyrid-4-yl)methylene-1-oxocyclohex-6-yl]azetidin-2-one is used as a potential pharmaceutical candidate for [application reason] due to its unique structure and potential biological activities. Further research and testing would be needed to fully understand its properties and potential uses.

Upstream product

• 76899-07-5 (3R,4R)-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]-4-acetoxyazetidin-2-one 

Downstream Products

• 1234051-70-7 C₄₄H₅₇N₂O₇PSi 

Relevant academic research and scientific papers

Preparation of the key intermediate in the synthesis of GV143253A: The anti-MRSA/E injectable trinem

GV143253A is a broad-spectrum injectable β-lactam belonging to the class of trinem antibiotics. A key intermediate (3S,4R)-3-[(1R)-1-(tert-butyldimethyl- silyloxy)ethyl]-4-[-(6′R)-2′-[(E)-(pyrid-4yl)methylene]- 1′-oxocyclohex-6′-yl]azetidin-2-one (10) was identified and synthesized via different enolate coupling approaches, using enol ether, lithium, sodium, magnesium, tin, zinc, zirconium, and titanium enolates. Among these approaches, the synthesis of (3S,4R)-3-[(1R)-1-(tert-butyldimethylsilyloxy)ethyl]-4-[-(6′R)- 2′-[(E)-(pyrid-4yl)-methylene]-1′-oxocyclohex-6′-yl] azetidin-2-one (10) via a titanium enolate offered advantages in terms of greater diastereoselectivity, higher yield, robustness, and isolation of intermediates and was superior to the method previously used for preparing large quantities of drug substance for early development studies.